OVIZIO IMAGING SYSTEMS

Their core work

Ovizio Imaging Systems is a Belgian medical technology SME specializing in optical and holographic imaging systems for biomedical applications. Their core technology appears to be digital holographic microscopy — a label-free, non-invasive method for analyzing cells and biological samples without staining. In the HoloCyt project, they applied this to build a rapid, low-cost cervical cancer screening platform, positioning their imaging technology as a point-of-care diagnostic tool. In TECHNOBEAT, they contributed their imaging expertise to a cardiac therapy research consortium, suggesting their platform is adaptable across tissue and cell types beyond oncology.

What they specialise in

How they've shifted over time

Both H2020 projects fall within a narrow 2016–2017 window, making a meaningful chronological evolution difficult to trace. What is visible is a shift in role: Ovizio joined TECHNOBEAT as a participant in a large cardiac research consortium, then led HoloCyt independently as coordinator — suggesting growing confidence in their own product roadmap. The move from participant in a multi-partner health RIA to sole coordinator of an SME Phase 1 grant points toward a company transitioning from research contributor to commercial technology developer.

Ovizio appears to be moving from being a specialist imaging component supplier inside larger consortia toward building and owning a standalone diagnostic product — the cervical cancer screening platform is the clearest signal of this commercial pivot.

How they like to work

Ovizio has experience on both sides of the consortium table: as a specialist technology partner inside TECHNOBEAT (a multi-partner RIA) and as project coordinator on HoloCyt. With only 7 unique partners across 5 countries and 2 projects, their network is small and targeted rather than broad. They are most likely to bring unique imaging hardware or software as a defined technology component, rather than leading large collaborative research programs.

Ovizio has collaborated with 7 unique partners across 5 countries within EU H2020, a compact but international network. Their geographic spread across 5 countries suggests engagement with pan-European health research communities, though the small partner count reflects a focused, project-specific rather than network-building collaboration style.

What sets them apart

Ovizio occupies a rare niche as a commercial SME bringing proprietary holographic imaging technology directly into EU health research projects — they are neither a university group nor a large medtech corporation, but a focused instrumentation company with validated applications in oncology and cardiology. Their SME Phase 1 coordination of HoloCyt shows they can translate research-grade imaging into a deployable clinical product, which is a capability most academic consortium partners cannot offer. For a consortium needing an imaging technology provider with commercial skin in the game, Ovizio is a strong fit.

Highlights from their portfolio

• HoloCyt
  Ovizio led this project as coordinator — a rare coordinator role for a small SME — targeting a globally high-impact clinical problem (cervical cancer screening) with a low-cost holographic platform, signaling genuine commercialization intent.
• TECHNOBEAT
  The largest single source of Ovizio's EU funding (€649,375), this cardiac therapy RIA placed Ovizio alongside clinical and research partners, validating their imaging technology in a high-stakes cardiovascular research environment.